Anadys Pharmaceuticals to Present at the Susquehanna SIGnificant Options in Healthcare...

Anadys Pharmaceuticals to Present at the Susquehanna SIGnificant Options in
Healthcare Conference

SAN DIEGO, Feb. 27 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc.
(Nasdaq: ANDS) announced today that it will present at the Susquehanna Second
Annual SIGnificant Options in Healthcare Conference on Tuesday, March 4, 2008
at 4:30 p.m. EST (1:30 p.m. PST). The conference is being held at the W Hotel
in New York.
Steve Worland, Ph.D., President and Chief Executive Officer of Anadys
Pharmaceuticals, Inc., will present an overview of Anadys and its two
development-stage product candidates, ANA598 and ANA773.
Additionally, Dr. Worland will participate as a panel member in a
discussion of the role of non-nucleoside and nucleoside polymerase inhibitors
in the future of HCV therapy at the conference on Wednesday, March 5 at
9:15 a.m.
The corporate presentation on Tuesday, March 4 will be simultaneously
webcast and can be accessed on the Investor Relations page of the Company's
website at http://www.anadyspharma.com. Listeners are encouraged to visit the
website approximately five minutes prior to the corporate presentation to
download or install any necessary software. A replay of the presentation will
be available approximately one hour after the live webcast concludes and will
be available through March 18, 2008.
About Anadys
Anadys Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to
improving patient care by developing novel medicines in the areas of hepatitis
C and oncology. The Company is developing ANA598, a small-molecule,
non-nucleoside inhibitor of the NS5B polymerase for the treatment of chronic
hepatitis C and ANA773, an oral TLR7 agonist prodrug for cancer.
Safe Harbor Statement
Statements in this press release that are not strictly historical in
nature constitute "forward-looking statements." Such statements include, but
are not limited to, references to Anadys' strategy, development programs, and
ability to develop novel medicines in the areas of hepatitis C and cancer.
Such forward-looking statements involve known and unknown risks, uncertainties
and other factors, which may cause Anadys' actual results to be materially
different from historical results or from any results expressed or implied by
such forward-looking statements. For example, the results of preclinical
studies may not be predictive of future results, and Anadys cannot provide any
assurances that ANA598 or ANA773 will not have unforeseen safety issues, will
have favorable results in future clinical trials or will receive regulatory
approval. Risk factors that may cause actual results to differ are discussed
in Anadys' SEC filings, including Anadys' Form 10-K for the year ended
December 31, 2006 and the "Risk Factors" section of Anadys' Form 10-Q for the
quarter ended September 30, 2007. All forward-looking statements are
qualified in their entirety by this cautionary statement. Anadys is providing
this information as of this date and does not undertake any obligation to
update any forward-looking statements contained in this document as a result
of new information, future events or otherwise.
SOURCE Anadys Pharmaceuticals, Inc.

investors, James T. Glover, SVP, Operations & CFO of Anadys Pharmaceuticals,
Inc., +1-858-530-3763, jglover@anadyspharma.com; or media, Ian Stone,
ian.stone@russopartnersllc.com, or David Schull,
david.schull@russopartnersllc.com, both of Russo Partners, LLC,
+1-619-814-3510, for Anadys Pharmaceuticals, Inc.